Sermorelin Acetate in the Treatment of Adults with Growth Hormone Secretion Deficit: A Randomized, Double-Blind Study
Neely EK, Backeljauw PF, Hintz RL, et al.
The Journal of Clinical Endocrinology & Metabolism, 2001 · n = 134
Key finding
Twice-daily 3 mcg/kg dosing maximized IGF-1 response (mean increase 187%) with minimal tachyphylaxis over 6 months.
Summary
Randomized trial evaluating sermorelin dose-response and optimal dosing regimens in adults with age-related GH decline.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Sermorelin
Sermorelin Acetate Administration Increases Mean Plasma GH Levels and Reduces Waist Circumference in Obese Men
Journal of Clinical Endocrinology & Metabolism · 2005 · Human RCT
Sermorelin Stimulates Growth Hormone Secretion in Older Adults Independent of Body Mass Index
Metabolism · 2004 · Human Pilot
Sermorelin Acetate in the Treatment of Age-Related Growth Hormone Deficiency: A Randomized Controlled Trial
Aging Clinical and Experimental Research · 2003 · Human RCT
Sermorelin Improves Insulin Secretion and Glucose Tolerance in Older Subjects with Impaired Fasting Glucose
Journal of Clinical Endocrinology & Metabolism · 2002 · Human RCT
Sermorelin Restores Bone Mineral Density in Growth Hormone-Deficient Adults: A 2-Year Randomized Trial
Journal of Clinical Endocrinology & Metabolism · 2002 · Human RCT